DENTSPLY SIRONA

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dentsply Sirona (XRAY) exceeds Q4 expectations, focuses on innovation

Dentsply Sirona (XRAY) reported strong financial performance in Q4 2022, with a strategic focus on digitalization and innovation. Despite challenges in organic sales and supply chain constraints, the company aims for margin improvement and growth opportunities through investments and pricing strategies. Restructuring efforts and acquisitions are set to drive profitability and market share gains.

Dentsply Sirona reports robust Q1 growth, eyes digital innovation

Dentsply Sirona's strong Q1 performance driven by Consumables and Aligners segments.
Challenges include mixed regional performance and cautious outlook on equipment demand.
Opportunities lie in digitalization, DSO partnerships, and growth in China and EPS targets.
Overall, a positive outlook with strategic focus on innovation and customer experience.

Dentsply Sirona exceeds Q2 expectations, eyes growth amid challenges

Dentsply Sirona reported strong financial performance in Q2 2023, exceeding expectations and raising full-year outlook across key financial metrics.
The company's strategic focus on growth, profitability, and digitalization, coupled with investments in key regions and product innovation, positions it for sustained success.
While facing challenges in certain markets and operational areas, Dentsply Sirona remains optimistic about opportunities for growth, innovation, and value creation in the dental industry.
Overall, Dentsply Sirona's performance highlights operational strengths, market positioning, and a forward-looking approach to driving shareholder value and market expansion.

DENTSPLY SIRONA reports mixed Q3 results, focuses on innovation and growth

DENTSPLY SIRONA's Q3 performance showed mixed results with challenges in certain markets but strength in key segments like CAD/CAM and Aligners.
The company is focused on driving value through innovation, maintaining a commitment to long-term plans, and navigating external challenges with confidence.
Despite headwinds, DENTSPLY SIRONA remains within guidance range for the year, with a strategic focus on volume growth and market expansion opportunities.

DENTSPLY SIRONA anticipates double-digit EPS growth in 2024

DENTSPLY SIRONA's Q4 2023 performance showed growth in key segments, with strategic initiatives set for 2024 as an inflection year for double-digit EPS growth.
The company is focusing on innovation, SKU optimization, and operational efficiency to drive profitability and revenue growth.
Challenges lie in certain segments and the need for organic growth normalization by 2025, but opportunities exist in new product launches and margin expansion.
Overall, DENTSPLY SIRONA is poised for accelerated profitable growth, with 2024 expected to be a pivotal year for improved performance.

DENTSPLY SIRONA reports mixed Q1 performance amidst innovation focus

DENTSPLY SIRONA navigated challenges in Q1 with a focus on innovation, sustainability, and strategic updates. While facing headwinds in certain segments and markets, the company aims to capitalize on growth opportunities through product launches and strategic initiatives.

DENTSPLY Sirona navigates revenue decline with strategic restructuring plans

DENTSPLY Sirona's Q2 performance reflects revenue decline and margin contraction, prompting strategic restructuring and focus on customer-centric initiatives. While facing challenges from macroeconomic factors and restructuring impacts, the company aims to leverage opportunities in shareholder returns and market dynamics to drive growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

DENTSPLY SIRONA Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

NEW YORK , Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who purchased shares of XRAY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders that lost money on Dentsply Sirona Inc.(XRAY) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

The Schall Law Firm Invites Stockholder Contributions To A Securities Fraud Case Against DENTSPLY SIRONA Inc.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between December 1, 2022 and November 6, 2024, both dates inclusive (the “Class Period”), of the important January 27, 2025 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Dentsply To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered losses exceeding $75,000 in Dentsply between December 1, 2022 and November 6 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DENTSPLY SIRONA Inc. ("Dentsply" or the "Company") (NASDAQ:XRAY) and reminds investors of the January 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DENTSPLY SIRONA

CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 10, 2025, to holders of record as of December 27, 2024.

Dentsply Sirona Declares Quarterly Cash Dividend

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=116200&wire=1 or contact Joseph E. Levi, Esq.

Dentsply Sirona Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 27, 2025 to Discuss Your Rights – XRAY

LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

The Schall Law Firm Invites Shareholder Contributions To A Fraud Case Against DENTSPLY SIRONA Inc.

NEW YORK , Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who purchased shares of XRAY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors who lost money on Dentsply Sirona Inc.(XRAY) should contact The Gross Law Firm about pending Class Action - XRAY

Market Forecast By Material, Design, Type, Price, Facility Type And Competitive Landscape Market Forecast By Material, Design, Type, Price, Facility Type And Competitive Landscape

Qatar Dental Implants Market Report 2024, Featuring Profiles of Biohorizons, Cefla, Implant Direct, Dentsply Sirona, Thommen Medical, Straumann Implantology, BEGO Implants, MegaGen and Camlog

LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

DENTSPLY SIRONA Inc Is Being Sued For Violating Securities Regulations And Affected Investors Are Urged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=115778&wire=1 or contact Joseph E. Levi, Esq.

January 27, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - XRAY

LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

The Schall Law Firm Invites Public Participation In A Fraud Case Against DENTSPLY SIRONA Inc.

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY).

Dentsply Sirona Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 27, 2025 to Discuss Your Rights – XRAY

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=115689&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Dentsply Sirona Inc. (XRAY) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

DENTSPLY SIRONA Inc Is Being Sued For Violating Securities Laws And Stockholders With Losses Are Encouraged To Contact The Schall Law Firm

XRAY continues to gain traction from a robust product portfolio. However, the suspension of Byte's business and macroeconomic factors, such as weakened global demand, persist.

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now

NEW YORK, NY / ACCESSWIRE / December 9, 2024 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=115531&wire=1 or contact Joseph E. Levi, Esq.

Dentsply Sirona Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – XRAY

NEW YORK , Dec. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who purchased shares of XRAY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

January 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against XRAY

LOS ANGELES, CA / ACCESSWIRE / December 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against DENTSPLY SIRONA Inc.

NEW YORK, Dec. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between December 1, 2022 and November 6, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 27, 2025.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

DENTSPLY SIRONA Inc Is Being Sued For Violating Securities Laws And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 1, 2022 and November 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 27, 2025.

The Schall Law Firm Invites Investor Participation In A Fraud Case Against DENTSPLY SIRONA Inc.

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=115102&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Dentsply Sirona Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – XRAY

NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between December 1, 2022 and November 6, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 27, 2025.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

News for DENTSPLY SIRONA Stock (XRAY)